⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL782363 | 0.97 | — | — | |
| SCHEMBL9642490 | 0.78 | — | — | |
| SCHEMBL2525941 | 0.78 | — | — | |
| SCHEMBL10037275 | 0.75 | — | — | |
| SCHEMBL18822178 | 0.75 | — | — | |
| SCHEMBL23903753 | 0.75 | GLRA1 (0.35) | — | |
| Hydrochloric Acid SCHEMBL5280142 | 0.75 | — | — | |
| Ethylenediamine SCHEMBL9124549 | 0.75 | PAOX (0.36) | — | |
| Hydrochloric Acid SCHEMBL31362880 | 0.73 | KDM4E (0.37) | — | |
| SCHEMBL28236301 | 0.73 | GLRA1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238711-B1 | Compounds and methods to inhibit or augment an inflammatory response | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. (GB) | 2007-07-03 | — | — | US | claimed |
| EP-4741018-A2 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-05-13 | — | — | EP | disclosed |
| US-12583836-B2 | Sulphonamide compounds | Anaxis Pharma Pty Ltd (AU) | 2026-03-24 | — | — | US | disclosed |
| EP-4168401-B1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-01-07 | — | — | EP | disclosed |
| WO-2025062334-A1 | 4-((5-(3-(4-(PYRIDIN-2-YL)CYCLOPENTYL)-1 H-PYRAZOL-3-YL)AMINO)-BENZENESULFONAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS CDK INHIBITORS FOR THE TREATMENT OF CANCER | BEIGENE SWITZERLAND GMBH (CH) | 2025-03-27 | — | — | WO | disclosed |
| US-20250074891-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-03-06 | — | — | US | disclosed |
| EP-4452966-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| US-20240109910-A1 | HEXAHYDRO-5,8-EPOXYCYCLOHEPTA[c]PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE CB1 AND / OR CB2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-04 | — | — | US | disclosed |
| US-20230348493-A1 | COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BEIJING GREATWAY PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348493-A1 | COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BEIJING GREATWAY PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| EP-0683792-A1 | LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6 | ABBOTT LABORATORIES (US) | 1995-11-29 | — | — | EP | disclosed |
| WO-1994014841-A1 | LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6 | ABBOTT LABORATORIES (US) | 1994-07-07 | — | — | WO | disclosed |
| US-5086184-A | Herbicides | DOWELANCO (US) | 1992-02-04 | — | — | US | disclosed |
| US-4943634-A | HERBICIDES | ELI LILLY AND COMPANY (US) | 1990-07-24 | — | — | US | disclosed |
| US-4801718-A | HERBICIDES | ELI LILLY AND COMPANY (US) | 1989-01-31 | — | — | US | disclosed |
| US-4636243-A | HERBICIDES ISOXAZOLES | ELI LILLY AND COMPANY (US) | 1987-01-13 | — | — | US | disclosed |
| US-4515625-A | HERBICIDES | ELI LILLY AND COMPANY (US) | 1985-05-07 | — | — | US | disclosed |
| EP-0049071-B1 | N-ARYLBENZAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1984-12-19 | — | — | EP | disclosed |
| US-4416683-A | HERBICIDES | ELI LILLY AND COMPANY (US) | 1983-11-22 | — | — | US | disclosed |
| EP-0049071-A1 | N-arylbenzamide derivatives | ELI LILLY AND COMPANY (US) | 1982-04-07 | — | — | EP | disclosed |